These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19084489)

  • 1. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique].
    Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ;
    Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Position statement regarding usage of biosimilars: position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique.
    ; ;
    Nephrol Ther; 2006 Dec; 2(7):432-5. PubMed ID: 17185233
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: pharmacovigilance and risk management.
    Zuñiga L; Calvo B
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.
    Aapro M; Krendyukov A; Schiestl M; Gascón P
    BioDrugs; 2018 Apr; 32(2):129-135. PubMed ID: 29417431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
    Combe C; Tredree RL; Schellekens H
    Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar peptides: need for pharmacovigilance.
    Joshi SR
    J Assoc Physicians India; 2011 Apr; 59 Suppl():44-7. PubMed ID: 21818998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.